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was conducted. RESULTS: Overall, 20,488 cases were included in the analysis. After         
the adjustment for age, sex, body-mass-index and duration of education there is a 
statistically signiﬁcant association between consumption of tobacco and HRQoL in 
all subscores as well as both composite scores of the SF-12. The regression coefﬁcients 
for current smoking (all non-smokers as reference group) are relatively small with 
0.68 (role physical) to 1.35 (general health) points for physical domains and 
between 0.58 (vitality) and 1.47 (mental health) points for mental domains. These 
differences increase considerable for elderly persons (age of 50 or older, N  9830) 
with 1.274 (role physical) to 1.87 (general health) points for physical and 0.953 
(vitality) to 1.682 (social functioning) for mental scales. Equally, there is a strong 
statistical association between the current amount of smoking (per 10 cigarettes per 
day) and HRQoL (0.342 to 0.858 for physical and 0.47 to 1.07 for mental 
domains, N  5560). CONCLUSIONS: In particular, the ﬁndings are limited by the        
inconclusive causality direction for smoking and mental health. However, these results 
conﬁrm the existing evidence concerning the negative association between smoking 
status or smoking intensity and HRQoL in a general population.
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OBJECTIVES: To validate the Spanish version of the speciﬁc questionnaire “COPD 
and asthma sleep impact scale (CASIS)” which measures the impact of sleep quality 
in patients with COPD on their HRQoL. METHODS: Observational, prospective, 
multicenter study in patients with moderate/severe COPD. Data were collected at 
inclusion and at day 15, including the Spanish version of CASIS (7 items, range: 7 
best–35 worst) and the “gold standard” Saint George Respiratory Questionnaire 
(SGRQ). Additionally, socio-demographics, clinical data and one item about self-
 perceived change in health status between visits were recorded. Feasibility, validity, 
reliability (internal consistency, test-retest) and responsiveness to change of the CASIS 
Spanish version were evaluated. RESULTS: A total of 142 patients were included, 
87.1% males, mean age (SD) was 67.4(8.2) years, 52.7% with primary studies, 75% 
former smokers, FEV1 (%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 
11.1% stage IV. Mean (SD) score in CASIS was 18.5(6.5). CASIS questionnaire 
showed low levels of absent information: the mean number of items not responded 
per patient was 0.1, and no item accumulated more than 1 missing response. Ceilling 
effects of CASIS (proportion of patients accumulated in the maximum possible score) 
were null, and ﬂoor effects (proportion of patients accumulated in the minimum pos-
sible score) were 7.5%. CASIS showed low internal consistency (Cronbach’s alpha 
0.50) but an excellent test-retest reliability among patients who reported subjective 
stability in their health status (inter-class correlation coefﬁcient  0.88). Correlations 
between CASIS and SGRQ global scores were high (0.71) and correlations between 
CASIS and SGRQ dimensions were moderate to high (0.62 to 0.69). Signiﬁcant dif-
ferences (p  0.01) in LCOPD were observed in exacerbated patients who reported 
an improvement, with a high effect size (0.90). CONCLUSIONS: According to pre-
liminary results, Spanish version of CASIS showed satisfactory psychometric proper-
ties in terms of feasibility, validity, reliability and responsiveness to change.
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OBJECTIVES: It is hypothesised that cough and/or sputum symptoms have a negative 
impact on health-related quality of life (HRQoL) in chronic obstructive pulmonary 
disease (COPD). This study assessed the impact of these symptoms on HRQoL in 396 
COPD patients. METHODS: Data were drawn from the Respiratory Adelphi Disease 
Speciﬁc Programme conducted in France, Germany, Italy, Spain, the UK and the USA 
in 2008. Information collected included physicians’ perceptions of symptom severity. 
Patients were invited to ﬁll out a questionnaire that included EQ-5D. Variables anal-
ysed were age, gender, body mass index, breathlessness, smoking status, co-morbidi-
ties (heart-related and anxiety/depression), compliance, most recent forced expiratory 
volume in 1 second (FEV1, if available) and country of origin. Due to a highly skewed 
EQ-5D distribution, three regression methods were applied (Tobit, OLS and GLM) 
to assess the impact of these variables on HRQoL. Final models derived included sta-
tistically signiﬁcant variables only (p  0.05). RESULTS: Using all three methods, 
cough and/or sputum were signiﬁcant predictors of worse HRQoL compared with 
COPD patients not experiencing these symptoms. FEV1 was only a signiﬁcant predic-
tor of better HRQoL in the Tobit approach. In this model, patients with moderate or 
severe cough and/or sputum symptoms presented with worse HRQoL compared with 
the wider COPD population (-0.09, 95% CI 0.14, 0.04). FEV1 values 30–50% 
predicted are associated with higher EQ-5D (0.006, p  0.05). However, no further 
signiﬁcant impact was present at FEV1 50% predicted. In the Tobit model, patients 
not viewed as fully compliant with the current drug regimen were also associated with 
worse EQ-5D (0.09, p  0.05). Similar statistically signiﬁcant variables were observed 
using the GLM and OLS models. CONCLUSIONS: Presence and severity of cough 
and/or sputum in COPD has a marked association with worse HRQoL, independent 
of FEV1 measurements. These results indicate unmet therapeutic needs in this 
population.
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OBJECTIVES: To validate the Spanish version of the quality of life (QoL) speciﬁc 
questionnaire for patients with COPD “Living with Chronic Obstructive Pulmonary 
Disease” (LCOPD). METHODS: Observational, prospective, multicenter study in a 
sample of patients with moderate/severe COPD. Data were collected at inclusion and 
at day 15, including the Spanish version of LCOPD (22 items, range: 22 worst—44 
best) and the “gold standard” Saint George Respiratory Questionnaire (SGRQ). 
Additionally, socio-demographics, clinical data and one item about self-perceived 
change in health status between visits were recorded. Feasibility, validity, reliability 
(internal consistency, test-retest) and responsiveness to change of the LCOPD Spanish 
version were evaluated. RESULTS: A total of 142 patients were included, 87.1% 
males, mean age (SD) was 67.4 (8.2) years, 52.7% with primary studies, 75% former 
smokers, FEV1 (%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 11.1% 
stage IV. Mean (SD) score in LCOPD was 33.0 (6.7). LCOPD questionnaire showed 
low levels of absent information: the mean number of items not responded per patient 
was 0.1, and no item accumulated more than 1 missing response. Floor and ceiling 
effects of LCOPD (proportion of patients accumulated in the minimum and maximum 
possible scores, respectively), were low (6%). LCOPD showed satisfactory levels of 
reliability: high internal consistency (Cronbach’s alpha  0.94) and excellent test-retest 
reliability among patients who reported subjective stability in their health status (inter-
class correlation coefﬁcient  0.92, p  0.001). Correlations between LCOPD and 
SGRQ global scores were very high (0.85), and correlations between LCOPD and 
SGRQ dimensions were moderate to high (0.60 to 0.87). Signiﬁcant differences (p  
0.05) in LCOPD were observed in exacerbated patients who reported an improvement, 
with a small to moderate effect size (0.31). CONCLUSIONS: According to preliminary 
results, Spanish version of LCOPD showed satisfactory psychometric properties in 
terms of feasibility, validity, reliability and responsiveness to change.
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OBJECTIVES: To validate the Spanish version of the health speciﬁc questionnaire to 
evaluate the impact of fatigue on patients with COPD “COPD and asthma fatigue 
scale (CAFS)”. METHODS: Observational, prospective, multicenter study in a sample 
of patients with moderate/severe COPD. Data were collected at inclusion and at day 
15, including the Spanish version of CAFS (12 items, range: 12 best–60 worst) and 
the “gold standard” Saint George Respiratory Questionnaire (SGRQ). Additionally, 
socio-demographics, clinical data and one item about self-perceived change in health 
status between visits were recorded. Feasibility, validity, reliability (internal consis-
tency, test-retest) and responsiveness to change of the CAFS Spanish version were 
evaluated. RESULTS: A total of 142 patients were included, 87.1% males, mean age 
(SD) was 67.4 (8.2) years, 52.7% with primary studies, 75% former smokers, FEV1 
(%)  48.5%, (SD  13.3), 51.3% stage II, 37.6% stage III and 11.1% stage IV. Mean 
(SD) score in CAFS was 36.7 (12.1). CAFS questionnaire showed low levels of absent 
information: the mean number of items not responded per patient was 0.1, and no 
item accumulated more than 1 missing response. Floor and ceiling effects of CAFS 
(proportion of patients accumulated in the minimum and maximum possible scores, 
respectively), were low (2%). CAFS showed satisfactory levels of reliability: high 
internal consistency (Cronbach’s alpha  0.88) and excellent test-retest reliability 
among patients who reported subjective stability in their health status (inter-class 
correlation coefﬁcient  0.85). Correlations between CAFS and SGRQ global scores 
were high (0.79), such as the correlations between CAFS and SGRQ dimensions (0.63 
to 0.74). Signiﬁcant differences (p  0.01) in LCOPD were observed in exacerbated 
patients who reported an improvement, with a high effect size (0.90). CONCLU-
SIONS: According to preliminary results, Spanish version of CAFS showed satisfactory 
psychometric properties in terms of feasibility, validity, reliability and responsiveness 
to change.
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Smoker Complaint Scale for the Turkish population. METHODS: The research 
was conducted in the university students. For pretest study forty students were chosen 
as a sampling group. After the assessment of the results, the Smoker Complaint Scale 
was applied to 250 students who quit smoking. Of the students are 54% female and 
46% male. The original instrument was translated into Turkish and then translated 
back into English by two independent translators. For psychometric measures, a small 
sample was used to check the initial comprehension and factibility. Cronbach’s Alfa 
was used to assess reliability and factor analysis to assess dimensionality. The 
EuroQol-5D was used for concurrent validity. RESULTS: The internal consistency 
coefﬁcient (Cronbach’s alpha) of SCS was 0.912. Factor analysis of the scale revealed 
that it was composed of 5 factors with Eigenvalues 1.0, accounting for 77.9% of the 
total variance. All the items of the Turkish SCS had a factor load ranging from 0.587 
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to 0.886 and they all belonged to 5 factors. There was a strong relationship between 
SCS and EuroQol 5D (r  between 0.46–0.76). CONCLUSIONS: The research sug-
gests that the validity and reliability of the Turkish SCS are satisfactory and that it 
can be used in Turkey.
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OBJECTIVES: Determine quality of life of COPD patients. METHODS: The medical 
records of 300 patients with acute exacerbation of COPD who visited City Clinical 
Hospital #2, with mean age 68.5 o 4.5 male and 64.8 o 3.4 female, were retrospec-
tively reviewed. Patients were evaluated on the criteria for COPD [2006]. Socio-
 demographic data, severity of disease, co-morbidity, and use of health resources in 
the previous years were collected. SF-36 quality of life questionnaire were administered 
to all patients. RESULTS: The mean FEV1 value was 45.9 o 9.1%. The severity of the 
disease was mild in 139 (46.3%) cases, moderate in 114 (38.0%), severe in 30 
(10.0%), very severe in 17 (5.7%). With regard to the use of health resources in the 
previous year, the mean values were: visits to physician 7,27 o 1,2 and hospital admis-
sions 8,16 o 0,31. The mean SF-36 scores for patients with mild COPD in the physical 
component before and after therapy were 84.5 o 4.2 and 91.2 o 5.8 with $ % value 
(9.2 o 1.6); moderate 73.2 o 3.1 and 77.6 o 4.6 with $ % value (6.0 o 1.5); severe 
42.2 o 1.2 and 45.2 o 2.6 with $ % (4.5 o 1.4); very severe 19.8 o 2.4 and 23.5 o 
3.8 with $ % value (4.2 o 1.4). Similarly, the mean SF-36 scores on mental component 
of all groups of patients under study, ranging from mild to very severe were 69.60 o 
2.1 and 72.3 o 3.4 with $ % value (3.1 o 2.3); 54.6 o 2.2 and 56.9 o 3.7 with $ % 
value (4.2 o 1.5); 38.0 o 2.3 and 39.6 o 3.1 with $ % 3.9 o 0.8; 28.2 o 1.1 and 29.1 
o 2.4 with $ % value (4.2 o 1.3). CONCLUSIONS: Patients had an increase functional 
dynamic index ($ %) of SF-36 in the physical component, and signiﬁcant reduction 
was only seen in mental component of patients with severe and very severe cases.
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OBJECTIVES: Mechanical ventilation for acute respiratory failure is likely to be a           
reliable indicator of critical care resource requirements on a population level. Our aim 
is to analyze the costs and discharge status for patients with respiratory failure needing 
mechanical ventilation (DRG code 475) in Spain and to examine the impact of age in 
terms of hospital outcome. METHODS: From the 2004 National Hospital Discharge 
Database all records aged 16 years with a ﬁnal DRG 475 were retrieved. This DRG, 
deﬁned as “respiratory system diagnosis with mechanical ventilation”, includes three 
procedure codes and is applied to patients undergoing mechanical ventilation for a 
variable period of time. Demographic characteristics, clinical outcomes and hospital-
resources utilization were examined. An exploratory logistic regression analysis was 
performed to identify factors associated with in-hospital mortality. To depict the 
amount of resources spent to procure a given level of desired outcome (hospital sur-
vival) we determined the cost per survivor based in the average national charges for 
DRG 475. RESULTS: 4267 cases were eligible for analysis. Mean age was 64 yr, 71%            
were men and 85% medical patients. According to Charlson index, 45% of cases had 
no associated comorbidity. Overall 36% of cases required prolonged mechanical 
ventilation. In-hospital mortality was 39%. Median LOS was 14 days. Total hospital 
costs were ª 42,581,929. Multivariate logistic regression showed that age signiﬁcantly 
correlated with in-hospital mortality after adjusting for comorbidities, principal cause 
of hospital admission and duration of mechanical ventilation. An inverse relationship 
between survival rate and age was observed and this resulted in an age-related 
increased cost per survivor. CONCLUSIONS: Age has a signiﬁcant impact on out-      
comes in patients under DRG 475. These analyses will help inform health care deci-
sion-making and resource planning in the face of an ageing population. This study  
has been supported by the Spanish National ID Program (grant number STPY 
1456/07).
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OBJECTIVES: Despite different licences for the use of inhaled corticosteroids/ long 
acting beta—agonist combination products for Chronic Obstructive Pulmonary 
Disease (COPD) and asthma, anecdotal evidence suggests general practitioners pre-
scribe similar formulations and doses for both diseases. For patients with COPD, 
where the licences are more restricted, this may lead to “off-label” prescribing. The 
objective of this study was to examine the frequency and nature of “off-label” pre-
scribing of combination products in COPD patients. METHODS: This was a retro-
spective cohort study using data from the General Practice Research Database 
(GPRD), a large nationally representative UK primary care database. All combined 
salmeterol/ﬂuticasone and formoterol/budesonide prescriptions written between 
Jan 2006 and Dec 2007 for patients with a Read code for COPD were selected. 
“Off-label” prescribing was deﬁned as any formulation and/ or dose of salmeterol/
ﬂuticasone or formoterol/budesonide not licensed for COPD. The proportion of 
“off-label” prescriptions was calculated for each of the 2 treatments and “off-label” 
prescriptions were further subdivided into whether they were “off-label” with respect 
to formulation or dose. All calculations were replicated at the patient level and 
reported in relation to age, sex and smoking status. RESULTS: The analyses were 
based on a total of 21,137 COPD patients receiving combination products (salme-
terol/ﬂuticasone: 17,115; formoterol/budesonide: 4,809) between 2006–2007. 77% of 
prescriptions were “off-label”, 71% for an incorrect formulation and 6% for an 
incorrect dose. 86% of salmeterol/ﬂuticasone prescriptions were “off-label” (85% 
formulation, 1% dose) versus 37% of formoterol/budesonide prescriptions (10% 
formulation, 27% dose). The most frequently prescribed unlicensed formulations 
were salmeterol 25 mcg/ﬂuticasone 250 mcg pMDI (45%) and salmeterol 25 mcg/
ﬂuticasone 125 mcg pMDI (20%). CONCLUSIONS: “Off-label” prescribing of com-
bination therapy in COPD patients is very common in the UK. The impact of off-label 
prescribing on efﬁcacy and patient safety is unknown; “off-label” prescribing poten-
tially represents an economically wasteful prescribing practice.
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OBJECTIVES: Due to cost reaching $10,000/season, respiratory syncytial virus (RSV) 
immunoprophylaxis is limited to high-risk periods, but season determination is heavily 
debated and absolute risk varies signiﬁcantly by geographic location. We present 
monthly RSV incidence rates to estimate absolute burden of disease and numbers 
needed to treat (NNT) to provide an alternative to a dichotomous season deﬁnition. 
METHODS: Medicaid fee-for service recipients 2 years old from California and 
Florida (1999–2004) were selected if they met high-risk criteria for RSV infections 
(chronic lung disease or congenital heart disease based on ICD-9 codes, or prematurity 
up to 32 weeks’ gestational age based on birth certiﬁcates). Monthly RSV hospitaliza-
tion rates were broken down by recipients’ age and adjusted for the effects of immu-
noprophylaxis. NNTs were calculated as inverse of the absolute risk reduction (based 
on relative risk reduction from clinical trial data: 50%). Results in Florida were sepa-
rated in 5 surveillance regions. RESULTS: California showed a very distinct season 
from December–March with almost zero viral activity outside. NNTs were smallest 
in February (50) but increased with increasing age. In Florida, no months had zero 
activity; however, NNTs were never below 125, regardless of age. Among children 1 
year, the lowest NNT was 252 [95% CI: 129–5,875] and NNTs exceeded 500 for 8 
months (January–August). While the northern regions showed a short, distinct season, 
the southern regions experienced prolonged activity, most obvious in the southeast. 
Yet, April through July in the southwest and May/June in the southeast showed NNTs 
exceeding 650 while the winter months had a peak activity that was comparable to 
other regions. CONCLUSIONS: NNTs can address differences in burden of disease 
during the RSV season and between geographic regions and assure equitable access 
to prophylaxis. Reduced RSV incidence in the second year of life should be incorpo-
rated in decisions for immunoprophylaxis.
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OBJECTIVES: Tobacco has been identiﬁed as a major risk factor for lung cancer, 
heart disease, and respiratory disease. Adults rarely visit their physicians for preventive 
care. But surveys have shown that more than half of adult smokers see a dentist each 
year for preventive care. This may put dentists in a better position to implement 
tobacco cessation interventions. The aim of the study was to investigate the tobacco 
cessation interventions conducted by dental practitioners in Japan. METHODS: The 
study used a survey mailed to dentists (n  1489) in three prefectures (Tokyo, Iwate, 
Yamanashi) asking about the practitioners’ tobacco cessation activities, patient demo-
graphic characteristics, barriers to counseling, and attitudes towards tobacco in 2008. 
RESULTS: The response rate was 57% (n  847). Dentists advised 22% of patients 
to cease tobacco. More than half of them used a pamphlet or other printed materials. 
However, nicotine replacement therapy was prescribed infrequently (nicotine patches 
in 3.2% and nicotine gum in 2.2% of patients). Asked whether dentists should 
perform tobacco cessation interventions in their ofﬁces, 76% said yes. The main 
barrier to cessation counseling was insufﬁcient time, followed by a lack of knowledge 
and tobacco cessation specialists to whom to refer patients. 85% of respondents had 
no education or training in promoting tobacco cessation. Twenty-two percent of all 
respondents were smokers. CONCLUSIONS: Few dentists perform tobacco cessation 
interventions in their ofﬁces. Nicotine replacement therapy was hardly prescribed at 
all. Dentists have a positive attitude towards tobacco cessation interventions and 
